Latest Zanamivir Stories

Global Phase 3 Clinical Trial to Study NT-300 for Treatment of Acute Uncomplicated Influenza TAMPA, Fla., April 18, 2013 /PRNewswire/ -- Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) The Phase 3 clinical trial has been initiated in the United States, will continue in Australia and New...

$44 Million Contract with U.S. Department of Health and Human Services to Fund Completion of Clinical Development and Preparation for Submission of New Drug Application for NT-300 TAMPA, Fla., Feb. 28, 2013 /PRNewswire/ -- Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the advanced development of NT-300 (nitazoxanide) as a treatment of acute uncomplicated influenza. The value of the cost plus fixed-fee contract...

redOrbit Staff & Wire Reports – Your Universe Online In their continuing battle against substances falsely claiming to be able to help treat or cure the flu, the U.S. Food and Drug Administration (FDA) is now targeting producers of dietary supplements and medicines claiming to be generic versions of drugs that have been approved by regulators. According to Reuters reporter Toni Clarke, the FDA sent letters to nine online supplement distributors warning them about making...

Computer chips of a type more commonly found in games consoles have been used by scientists at the University of Bristol to reveal how the flu virus resists anti-flu drugs such as Relenza and Tamiflu. Professor Adrian Mulholland and Dr Christopher Woods from Bristol’s School of Chemistry, together with colleagues in Thailand, used graphics processing units (GPUs) to simulate the molecular processes that take place when these drugs are used to treat the H1N1-2009 strain of influenza –...

ALBANY, N.Y., April 17, 2012 /PRNewswire/ -- AMRI (NYSE: AMRI), a leading global contract research and manufacturing organization, was selected by Biota Holdings Limited (ASX: BTA), a leading anti-infective drug development company based in Australia, to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. AMRI will provide these services to support a New Drug Application for laninamivir to the United...

Incomplete availability of data has hampered a thorough assessment of the evidence for using the anti-influenza drug oseltamivir, a Cochrane Review has found. However, after piecing together information from over 16,000 pages of clinical trial data and documents used in the process of licensing oseltamivir (Tamiflu) by national authorities, a team of researchers has raised critical questions about how well the drug works and about its reported safety profile. The new analysis shows...

TAMPA, Fla., Oct. 21, 2011 /PRNewswire/ -- Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) The clinical trial enrolled 624 patients at 74 outpatient primary care centers...

SAN DIEGO, Aug. 15, 2011 /PRNewswire/ -- NexBio announced top line data from a Phase 2 clinical trial of DAS181, an investigational drug for treatment and prophylaxis of Influenza-Like Illness (ILI) caused by all types and strains of influenza and parainfluenza viruses, including pandemic influenza strains. In a double-blind, placebo-controlled, Phase 2 trial of otherwise healthy adults infected with influenza virus, treatment with DAS181 resulted in a significant reduction in patients'...

Studies highlight need for new antiviral treatment options and strategiesTwo new studies raise public health concerns about increasing antiviral resistance among certain influenza viruses, their ability to spread, and a lack of alternative antiviral treatment options. The findings are published in the January 1 issue of The Journal of Infectious Diseases. (Please see below for links to these articles online.)Influenza viruses are treated with two classes of drugs: M2 blockers (adamantanes)...

(Ivanhoe Newswire) -- In adults with seasonal influenza A virus infection, the combination of the drugs oseltamivir (tamiflu) and zanamivir (relenza) is less effective than oseltamivir monotherapy and not significantly more effective than zanamivir monotherapy.In the past few years oseltamivir and zanamivir have been key drugs for limiting the impact of seasonal influenza both in individuals (by reducing morbidity and mortality) and collectively (by slowing the virus' spread to buy time for...